You are here:---New antibiotic shows promise for treating MRSA pneumonia

New antibiotic shows promise for treating MRSA pneumonia

A drug approved two years ago for treating bacterial infections may hold promise for treating potentially fatal methicillin-resistant Staphylococcus aureus pneumonia, according to a recent study.

Researchers found patients treated with the antibiotic ceftaroline fosamil, or CPT-F, had a lower mortality rate after 28 days than the mortality rate seen in patients treated with vancomycin, the most common drug therapy for MRSA pneumonia. The study, presented Sept. 11 at the annual Interscience Conference on Antimicrobial Agents and Chemotherapy meeting in Denver, took place at Henry Ford Hospital in Detroit.

In the retrospective study, 33 of 38 patients responded well to treatments of CPT-F and were discharged from the hospital after the infection cleared. Of the five patients who died, three were attributed to other serious medical conditions.

The mortality rate for patients treated with vancomycin has been reported to be as high as 32% after 28 days. In the Henry Ford study, the mortality rate for the CPT-F treated population was 13%.

Of the 38 patients researchers evaluated, 20 were failing standard treatment with either vancomycin and/or cefepime, and were switched to CPT-F. Researchers said no complications were reported in those 20 patients.

“Many things fall under the umbrella of proper and appropriate MRSA pneumonia treatment, and these results present a possible benefit with the use of CPT-F,” Samia Arshad, a Henry Ford Infectious Diseases epidemiologist and the study’s lead author, said in a news release. “It is critical for us to find alternative drug therapies to improve patient outcomes. Further research is needed to test the efficacy of CPT-F on a larger patient population as CPT-F offers doctors another viable option for treating patients with MRSA pneumonia.”

In 2010 the Food and Drug Administration approved CPT-F, an injectable antibiotic, for treating patients with bacterial infections such as community-acquired bacterial pneumonia and skin infections. Henry Ford’s study is the first to evaluate the efficacy of MRSA pneumonia patients treated with CPT-F. MRSA pneumonia is highly antibiotic-resistant and most common in patients 65 or older.

The researchers plan to continue to look for other patients treated with CPT-F for MRSA pneumonia then match these patients to others treated with different antibiotics to conduct a matched cohort analysis.

The study was funded by Forest Laboratories Inc.

By | 2013-09-16T00:00:00-04:00 September 16th, 2013|Categories: National|0 Comments

About the Author:


Leave A Comment